Log in

Relevant bibliographies by topics / Maytansinoids

Contents

Journal articles
Dissertations / Theses
Book chapters
Conference papers

Academic literature on the topic 'Maytansinoids'

Author: Grafiati

Published: 14 March 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Maytansinoids.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Maytansinoids"

1

Giles, Francis, Rodica Morariu-Zamfir, John Lambert, et al. "Phase I Study of AVE9633, an AntiCD33-Maytansinoid Immunoconjugate, Administered as an Intravenous Infusion in Patients with Refractory/Relapsed CD33-Positive Acute Myeloid Leukemia (AML)." Blood 108, no. 11 (2006): 4548. http://dx.doi.org/10.1182/blood.v108.11.4548.4548.

Full text

Abstract:

Abstract AVE9633 is an immunoconjugate created by conjugation of the cytotoxic maytansinoid, DM4, to the monoclonal IgG1 antibody, huMy9-6 (average of 3.5 molecules of DM4 per antibody). The huMy9-6 antibody is a humanized version of a murine monoclonal antibody, My9-6, which is specific for the CD33 antigen expressed on the surface of myeloid cells, including the majority of cases of AML. Because CD33 has little expression outside the hematopoietic system, it represents an attractive target for antibody-based therapy in patients with AML. The humanized antibody, huMy9-6, binds to the CD33 ant

APA, Harvard, Vancouver, ISO, and other styles

2

Plattner, Ronald D., and Richard G. Powell. "Tandem Mass Spectrometry of Maytansinoids." Journal of Natural Products 49, no. 3 (1986): 475–82. http://dx.doi.org/10.1021/np50045a016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Larson, Gretchen M., Brian T. Schaneberg, and Albert T. Sneden. "Two New Maytansinoids fromMaytenus buchananii." Journal of Natural Products 62, no. 2 (1999): 361–63. http://dx.doi.org/10.1021/np9803732.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Messuti, Eleonora, Bruno Achutti Duso, Alessia Castiglioni, et al. "Abstract 513: Intra-tubular damage is targeted by maytansinoids and rescued by NF1: Revisiting mechanism and biomarkers of an established ADC payload." Cancer Research 84, no. 6_Supplement (2024): 513. http://dx.doi.org/10.1158/1538-7445.am2024-513.

Full text

Abstract:

Abstract There is great interest in the identification of biomarkers to guide development of antibody-drug conjugates (ADC). We previously showed that loss of Neurofibromatosis 1 (NF1), a gene frequently mutated across cancers, enhances the activity of DM1, the maytansinoid payload of T-DM1, through a novel function in regulating microtubule (MT) dynamics. Maytansinoids are puzzlingly more effective in cells (in the nanomolar range) vs in vitro (in the micromolar range). Since maytansinoids bind at the interface between tubulin dimers, they are thought to only bind soluble tubulin dimers or MT

APA, Harvard, Vancouver, ISO, and other styles

5

Xu, Mengyao, Bo Rueda, David Spriggs, and Yeku Oladapo. "Abstract 2884: Development of antibody drug conjugates targeting MUC16 in ovarian cancer subtypes." Cancer Research 85, no. 8_Supplement_1 (2025): 2884. https://doi.org/10.1158/1538-7445.am2025-2884.

Full text

Abstract:

Abstract Background: Ovarian cancer (OC) remains a formidable challenge due to limited treatment options and inevitable development of multidrug resistance. Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic modality, particularly for cancers with high unmet needs such as ovarian cancer (OC). MUC16, also known as CA125, is a high-molecular-weight glycoprotein overexpressed in ovarian cancer, serving as a biomarker for diagnosis and monitoring while contributing to tumor progression and immune evasion. Our laboratory previously identified 4H11, an antibody that preferential

APA, Harvard, Vancouver, ISO, and other styles

6

Lo, Chen-Fu, Tai-Yu Chiu, Yu-Tzu Liu, et al. "Synthesis and Evaluation of Small Molecule Drug Conjugates Harnessing Thioester-Linked Maytansinoids." Pharmaceutics 14, no. 7 (2022): 1316. http://dx.doi.org/10.3390/pharmaceutics14071316.

Full text

Abstract:

Ligand-targeting drug conjugates are a class of clinically validated biopharmaceutical drugs constructed by conjugating cytotoxic drugs with specific disease antigen targeting ligands through appropriate linkers. The integrated linker-drug motif embedded within such a system can prevent the premature release during systemic circulation, thereby allowing the targeting ligand to engage with the disease antigen and selective accumulation. We have designed and synthesized new thioester-linked maytansinoid conjugates. By performing in vitro cytotoxicity, targeting ligand binding assay, and in vivo

APA, Harvard, Vancouver, ISO, and other styles

7

Nittoli, Thomas, Frank Delfino, Marcus Kelly, et al. "Antibody drug conjugates of cleavable amino-benzoyl-maytansinoids." Bioorganic & Medicinal Chemistry 28, no. 23 (2020): 115785. http://dx.doi.org/10.1016/j.bmc.2020.115785.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Suchocki, John A., and Albert T. Sneden. "New maytansinoids: reduction products of the C(9)-carbinolamide." Journal of Organic Chemistry 53, no. 17 (1988): 4116–18. http://dx.doi.org/10.1021/jo00252a047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ladino, Cynthia A., Ravi V. J. Chari, Lizabeth A. Bourret, Nancy L. Kedersha, and Victor S. Goldmacher. "Folate-maytansinoids: Target-selective drugs of low molecular weight." International Journal of Cancer 73, no. 6 (1997): 859–64. http://dx.doi.org/10.1002/(sici)1097-0215(19971210)73:6<859::aid-ijc16>3.0.co;2-#.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Perrino, Elena, Martina Steiner, Nikolaus Krall, et al. "Curative Properties of Noninternalizing Antibody–Drug Conjugates Based on Maytansinoids." Cancer Research 74, no. 9 (2014): 2569–78. http://dx.doi.org/10.1158/0008-5472.can-13-2990.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Maytansinoids"

1

Hodgson, D. M. "Synthetic studies towards the maytansinoids." Thesis, University of Southampton, 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.330146.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Princiotto, S. "Synthesis of intermediates for the preparation of Active Pharmaceutical Ingredients (APIs)." Doctoral thesis, Università di Siena, 2020. http://hdl.handle.net/11365/1095607.

Full text

Abstract:

Maytansinoids are ansa macrocycles extracted from shrubs of Maytenus ovatus. Their anticancer activity is known since the 1970s, but it could be possible to be exploited only recently, as conjugated to different antibody in the context of antibody drug conjugates (ADCs). This kind of approach allowed to drive the pharmacologically active compound (payload) selectively towards the target cancer cells, avoiding to exert the cytotoxicity also in healthy cells. Ansamitocin P3, isolated from fermentation of Actinosynnema pretiosum, is a useful precursor for the preparation of DM1, the payload prese

APA, Harvard, Vancouver, ISO, and other styles

3

Meurer, Kristina. "Untersuchungen zum Vorkommen von Maytansinoiden in Höheren Pflanzen : ein Beitrag zur Suche nach einem maytansinproduzierenden Mikroorganismus /." [S.l. : s.n.], 2002. http://www.gbv.de/dms/bs/toc/356980243.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Brünjes, Marco. "Studien zur chemoenzymatischen Synthese und Biosynthese von Maytansinoid-Analoga." [S.l.] : [s.n.], 2006. http://deposit.ddb.de/cgi-bin/dokserv?idn=98052542X.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Frenzel, Thomas. "Studien zur chemoenzymatischen Synthese von Maytansinoid-Analoga Synthese von seco-Proansamitocin /." [S.l.] : [s.n.], 2005. http://deposit.ddb.de/cgi-bin/dokserv?idn=977228118.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Brünjes, Marco [Verfasser]. "Studien zur chemoenzymatischen Synthese und Biosynthese von Maytansinoid-Analoga / von Marco Brünjes." 2006. http://d-nb.info/98052542X/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

MERLINO, GIUSEPPE. "Characterization of MEN1309/OBT076, a new antibody conjugated to the DM4 maytansinoide toxin." Doctoral thesis, 2020. http://hdl.handle.net/11573/1341225.

Full text

Abstract:

CD205 is a type I transmembrane glycoprotein, member of C-type lectin receptor family. Analysis by mass spectrometry revealed that CD205 antigen was robustly expressed and highly prevalent in a variety of solid malignancies of different histotypes. Immunohistochemistry (IHC) confirmed the increased expression of CD205 antigen in pancreatic, bladder and triple negative breast cancer (TNBC) malignancies compared to corresponding normal tissues. Using immunofluorescence microscopy, rapid internalization of the CD205 antigen was observed. These results supported the development of MEN1309/OBT076,

APA, Harvard, Vancouver, ISO, and other styles

8

Frenzel, Thomas [Verfasser]. "Studien zur chemoenzymatischen Synthese von Maytansinoid-Analoga : Synthese von seco-Proansamitocin / von Thomas Frenzel." 2005. http://d-nb.info/977228118/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Maytansinoids"

1

Erickson, Hans. "Antibody-Maytansinoid Conjugates: From the Bench to the Clinic." In Drug Delivery in Oncology. Wiley-VCH Verlag GmbH & Co. KGaA, 2011. http://dx.doi.org/10.1002/9783527634057.ch13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Widdison, Wayne C. "CHAPTER 5. Maytansinoid Payloads for Antibody–Drug Conjugates (ADCs)." In Cytotoxic Payloads for Antibody–Drug Conjugates. Royal Society of Chemistry, 2019. http://dx.doi.org/10.1039/9781788012898-00100.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Lambert, John M., Veronique Blanc, Nathalie Le Bail, and Anne Bousseau. "Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies." In Antibody-Drug Conjugates and Immunotoxins. Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-5456-4_9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

"Maytansinoids." In Encyclopedia of Genetics, Genomics, Proteomics and Informatics. Springer Netherlands, 2008. http://dx.doi.org/10.1007/978-1-4020-6754-9_9986.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

"Ansamitocins (Maytansinoids)." In Anticancer Agents from Natural Products. CRC Press, 2011. http://dx.doi.org/10.1201/b11185-21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

"Ansamitocins (Maytansinoids)." In Anticancer Agents from Natural Products. CRC Press, 2005. http://dx.doi.org/10.1201/9781420039658-21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Maytansinoids"

1

Sala, Gianluca, Emily Capone, Enza Piccolo, et al. "Abstract 748: Non-internalizing site-specific antibody-drug conjugates based on maytansinoids display curative properties." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-748.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Nollmann, Friederike I., Patricia Perez Galan, Javier Garcia Fernandez, et al. "Abstract 1657: Structure-activity relationship studies and biological evaluation of novel maytansinoids, a class of highly selective tubulin inhibitors." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1657.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Nollmann, Friederike I., Patricia Perez Galan, Javier Garcia Fernandez, et al. "Abstract 2661: Novel albumin-binding maytansinoids inducing long-term partial and complete tumor regressions in several human cancer xenograft models in nude mice." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-2661.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Whiteman, Kathleen R., Holly A. Johnson, Xiuxia Sun, et al. "Abstract 4628: Anti-tumor activity and pharmacokinetics of the anti-FOLR1-maytansinoid conjugate IMGN853 is maintained over a wide range of maytansinoid-to-antibody ratios." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-4628.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Widdison, Wayne C., Sharon Wilhelm, Karen Veale, et al. "Abstract 2668: Detoxification of metabolites from antibody-maytansinoid conjugates by human liver microsomes." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2668.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Sun, Xiuxia, Jose F. Ponte, Nicholas C. Yoder, et al. "Abstract 4531: Effects of drug load on therapeutic index for antibody-maytansinoid conjugates." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4531.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Abbood, Ayat, Dima Aldiab, and Nasser Thalaj. "Characterization of Charge Variant Profile of Non-Cleavable Conjugated Antibodies." In 5th International Conference on Biomedical and Health Sciences. Cihan University-Erbil, 2024. http://dx.doi.org/10.24086/biohs2024/paper.1348.

Full text

Abstract:

The objective of this work was to study the charge variant profile of some monoclonal antibodies (mAbs) conjugated to maytansine derivative (mAb-1) or tomaymycin molecules (mAb-2 and mAb-3) via non-cleavable linkers. The imaging capillary isoelectric focusing method (icIEF) was emolpyed for this purpose. Initially, the charge variant profiles were determined for the three naked mAbs. The analysis revealed that these mAbs exhibited major species as well as minor species. Specifically, mAb-1 and mAb-2 displayed two charge species (pI values: 9.00 and 8.95). In the case of mAb-3, a main charge va

APA, Harvard, Vancouver, ISO, and other styles

8

Kellogg, Brenda, Charlene Audette, Hans Erickson, et al. "Abstract 4404: Comparativein vivopharmacokinetic properties of antibody-maytansinoid conjugates with alternative non-cleavable linkers." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-4404.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Singh, Rajeeva, Nathan Fishkin, Yelena Kovtun, et al. "Abstract C164: New tri-glycyl peptide linker offers advantages for maytansinoid antibody-drug conjugates (ADCs)." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-c164.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Ab, Olga, Laura M. Bartle, Lingyun Rui, et al. "Abstract 4576: IMGN853, an anti-Folate Receptor I antibody-maytansinoid conjugate for targeted cancer therapy." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-4576.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!